Cargando…

A post hoc analysis of the effect of viloxazine extended-release capsules on learning and school problems in children and adolescents with attention-deficit/hyperactivity disorder

Improvement in attention-deficit/hyperactivity disorder (ADHD) symptoms vs. placebo was reported in a series of pediatric clinical trials of viloxazine extended-release capsules (viloxazine ER; Qelbree™). This post hoc analysis of those studies evaluated the effect of viloxazine ER on learning and s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Faraone, Stephen V., Gomeni, Roberto, Hull, Joseph T., Busse, Gregory D., Melyan, Zare, Rubin, Jonathan, Nasser, Azmi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2021
Materias:	Original Contribution
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10038940/ https://www.ncbi.nlm.nih.gov/pubmed/34581911 http://dx.doi.org/10.1007/s00787-021-01877-5

Ejemplares similares

Executive Function Outcome of Treatment with Viloxazine Extended-Release Capsules in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Post-Hoc Analysis of Four Randomized Clinical Trials
por: Faraone, Stephen V., et al.
Publicado: (2021)

The role of placebo response in the efficacy outcome assessment in viloxazine extended‐release pivotal trials in paediatric subjects with attention‐deficit/hyperactivity disorder
por: Nasser, Azmi, et al.
Publicado: (2022)

Response of peer relations and social activities to treatment with viloxazine extended‐release capsules (Qelbree(®)): A post hoc analysis of four randomized clinical trials of children and adolescents with attention‐deficit/hyperactivity disorder
por: Faraone, Stephen V., et al.
Publicado: (2023)

The Effect of Viloxazine Extended-Release Capsules on Functional Impairments Associated with Attention-Deficit/Hyperactivity Disorder (ADHD) in Children and Adolescents in Four Phase 3 Placebo-Controlled Trials
por: Nasser, Azmi, et al.
Publicado: (2021)

Population Pharmacokinetics of Viloxazine Extended‐Release Capsules in Pediatric Subjects With Attention Deficit/Hyperactivity Disorder
por: Nasser, Azmi, et al.
Publicado: (2021)

A Phase 3, Placebo-Controlled Trial of Once-Daily Viloxazine Extended-Release Capsules in Adolescents With Attention-Deficit/Hyperactivity Disorder
por: Nasser, Azmi, et al.
Publicado: (2021)

Evaluating the likelihood to be helped or harmed after treatment with viloxazine extended‐release in children and adolescents with attention‐deficit/hyperactivity disorder
por: Nasser, Azmi, et al.
Publicado: (2021)

A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder
por: Nasser, Azmi, et al.
Publicado: (2022)

Model-Based Approach for Establishing the Predicted Clinical Response of a Delayed-Release and Extended-Release Methylphenidate for the Treatment of Attention-Deficit/Hyperactivity Disorder
por: Gomeni, Roberto, et al.
Publicado: (2020)

Translating Attention-Deficit/Hyperactivity Disorder Rating Scale-5 and Weiss Functional Impairment Rating Scale-Parent Effectiveness Scores into Clinical Global Impressions Clinical Significance Levels in Four Randomized Clinical Trials of SPN-812 (Viloxazine Extended-Release) in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder
por: Nasser, Azmi, et al.
Publicado: (2021)

Extended-Release Viloxazine Compared with Atomoxetine for Attention Deficit Hyperactivity Disorder
por: Price, Maxwell Z., et al.
Publicado: (2023)

Authors’ Reply to Singh and Balasundaram: Comment on “A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder”
por: Nasser, Azmi, et al.
Publicado: (2022)

Viloxazine in the Treatment of Attention Deficit Hyperactivity Disorder
por: Edinoff, Amber N., et al.
Publicado: (2021)

Pharmacokinetics of Coadministered Viloxazine Extended-Release (SPN-812) and Lisdexamfetamine in Healthy Adults
por: Faison, Shamia L., et al.
Publicado: (2021)

Authors’ Reply to Pande et al. Comment on “Extended-Release Viloxazine Compared to Atomoxetine for Attention Deficit Hyperactivity Disorder”
por: Price, Maxwell Z., et al.
Publicado: (2023)

Efficacy of Amphetamine Extended-Release Oral Suspension in Children with Attention-Deficit/Hyperactivity Disorder: Effect Size Across the Day
por: Faraone, Stephen V., et al.
Publicado: (2023)

Pharmacokinetics of Coadministered Viloxazine Extended-Release (SPN-812) and Methylphenidate in Healthy Adults
por: Faison, Shamia L., et al.
Publicado: (2020)

Viloxazine for Attention-Deficit Hyperactivity Disorder: A Systematic Review and Meta-analysis of Randomized Clinical Trials
por: Singh, Alok, et al.
Publicado: (2022)

Impact of a High-Fat Meal and Sprinkled Administration on the Bioavailability and Pharmacokinetics of Viloxazine Extended-Release Capsules (Qelbree(TM)) in Healthy Adult Subjects
por: Wang, Zhao, et al.
Publicado: (2021)

The influence of comorbid oppositional defiant disorder on white matter microstructure in attention-deficit/hyperactivity disorder
por: van Ewijk, Hanneke, et al.
Publicado: (2015)

Differential utility of teacher and parent–teacher combined information in the assessment of Attention Deficit/Hyperactivity Disorder symptoms
por: Garcia-Rosales, Alexandra, et al.
Publicado: (2020)

Genetics of attention deficit hyperactivity disorder
por: Faraone, Stephen V., et al.
Publicado: (2018)

Stimulant treatment profiles predicting co-occurring substance use disorders in individuals with attention-deficit/hyperactivity disorder
por: Groenman, Annabeth P., et al.
Publicado: (2019)

Effect of Aptensio XR (Methylphenidate HCl Extended-Release) Capsules on Sleep in Children with Attention-Deficit/Hyperactivity Disorder
por: Owens, Judith, et al.
Publicado: (2016)

Continuity in features of anxiety and attention deficit/hyperactivity disorder in young preschool children
por: Overgaard, Kristin Romvig, et al.
Publicado: (2014)

Risk factors for comorbid oppositional defiant disorder in attention-deficit/hyperactivity disorder
por: Noordermeer, Siri D. S., et al.
Publicado: (2017)

Impact of Paroxetine, a Strong CYP2D6 Inhibitor, on SPN‐812 (Viloxazine Extended‐Release) Pharmacokinetics in Healthy Adults
por: Wang, Zhao, et al.
Publicado: (2021)

A Phase II Double-Blind, Placebo-Controlled, Efficacy and Safety Study of SPN-812 (Extended-Release Viloxazine) in Children With ADHD
por: Johnson, Janet K., et al.
Publicado: (2019)

Maternal serum Vitamin B12 and offspring attention-deficit/hyperactivity disorder (ADHD)
por: Sourander, Andre, et al.
Publicado: (2020)

Predictive validity of attention-deficit/hyperactivity disorder from ages 3 to 5 Years
por: Overgaard, Kristin Romvig, et al.
Publicado: (2021)

Maternal serum C-reactive protein (CRP) and offspring attention deficit hyperactivity disorder (ADHD)
por: Chudal, Roshan, et al.
Publicado: (2019)

Suggestive diagnosis of attention-deficit/hyperactivity disorder in indigenous children and adolescents from the Brazilian Amazon
por: e Azevêdo, Paulo Verlaine Borges, et al.
Publicado: (2019)

Sleep, chronotype, and sleep hygiene in children with attention-deficit/hyperactivity disorder, autism spectrum disorder, and controls
por: van der Heijden, K. B., et al.
Publicado: (2017)

Beliefs regarding medication and side effects influence treatment adherence in adolescents with attention deficit hyperactivity disorder
por: Emilsson, Maria, et al.
Publicado: (2016)

Maternal personality traits moderate treatment response in the Multimodal Treatment Study of attention-deficit/hyperactivity disorder
por: Perez Algorta, Guillermo, et al.
Publicado: (2019)

Attention-deficit/hyperactivity disorder from preschool to school age: change and stability of parent and teacher reports
por: Overgaard, Kristin Romvig, et al.
Publicado: (2022)

A 6-year follow-up of a large European cohort of children with attention-deficit/hyperactivity disorder-combined subtype: outcomes in late adolescence and young adulthood
por: van Lieshout, Marloes, et al.
Publicado: (2016)

Viloxazine in the Management of CNS Disorders: A Historical Overview and Current Status
por: Findling, Robert L., et al.
Publicado: (2021)

A Pharmacokinetic Study of Methylphenidate Hydrochloride Multilayer Extended-Release Capsules (Aptensio XR(®)) in Preschool-Aged Children with Attention-Deficit/Hyperactivity Disorder
por: Adjei, Akwete L., et al.
Publicado: (2020)

Health-related quality of life of children with attention-deficit/hyperactivity disorder versus children with diabetes and healthy controls
por: Coghill, David, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_virkdd1ivhvfigaprm7dn7i8jg